|
| | |
|
Am J Psychiatry 1995; 152:613-615
Copyright © 1995 by American Psychiatric Association
Effect of naltrexone on alcohol "high" in alcoholics
JR Volpicelli, NT Watson, AC King, CE Sherman and CP O'Brien
Department of Psychiatry, University of Pennsylvania, Philadelphia 19104.
OBJECTIVE: Subjective effects of alcohol in alcoholics treated with
naltrexone or placebo were compared. METHOD: In a previously reported
double-blind clinical trial of 50 mg/day of naltrexone or placebo for
treatment of alcoholism, 36 of 70 detoxified male veterans deviated from
abstinence. Of these 36, 29 subsequently reported on the subjective effects
of drinking during the trial. RESULTS: A larger proportion of
naltrexone-treated subjects (seven of 12) than placebo- treated subjects
(two of 17) reported that the "high" produced by alcohol during the study
was significantly less than usual. The naltrexone-treated subjects also
drank less alcohol than the placebo- treated subjects during the first
drinking episode. There was no difference between groups in reported
intoxication, craving, memory, or loss of temper. CONCLUSIONS: The lower
alcohol consumption by the naltrexone-treated subjects may have resulted
from naltrexone's blockage of the pleasure produced by alcohol.
This article has been cited by other articles:
|
|
|
|
 
C. P. O'Brien
Prospects for a Genomic Approach to the Treatment of Alcoholism
Arch Gen Psychiatry,
February 1, 2008;
65(2):
132 - 133.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rosner, S. Leucht, P. Lehert, and M. Soyka
Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes
J Psychopharmacol,
January 1, 2008;
22(1):
11 - 23.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. A. Ray and K. E. Hutchison
Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-blind Placebo-Controlled Study
Arch Gen Psychiatry,
September 1, 2007;
64(9):
1069 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. SWIFT
Emerging approaches to managing alcohol dependence
Am. J. Health Syst. Pharm.,
March 1, 2007;
64(5_Supplement_3):
S12 - S22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Dermatis and M. Galanter
Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders
Focus,
January 1, 2007;
5(2):
141 - 150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. RUBIO, G. PONCE, R. RODRIGUEZ-JIMENEZ, M. A. JIMENEZ-ARRIERO, J. HOENICKA, and T. PALOMO
CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE?
Alcohol Alcohol.,
May 1, 2005;
40(3):
227 - 233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Heinz, M. Reimold, J. Wrase, D. Hermann, B. Croissant, G. Mundle, B. M. Dohmen, D. H. Braus, G. Schumann, H.-J. Machulla, et al.
Correlation of Stable Elevations in Striatal {micro}-Opioid Receptor Availability in Detoxified Alcoholic Patients With Alcohol Craving: A Positron Emission Tomography Study Using Carbon 11-Labeled Carfentanil
Arch Gen Psychiatry,
January 1, 2005;
62(1):
57 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. O'BRIEN
The Mosaic of Addiction
Am J Psychiatry,
October 1, 2004;
161(10):
1741 - 1742.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Chen and A. J. Lawrence
Chronic Antidepressant Treatment Causes a Selective Reduction of {micro}-Opioid Receptor Binding and Functional Coupling to G Proteins in the Amygdala of Fawn-Hooded Rats
J. Pharmacol. Exp. Ther.,
September 1, 2004;
310(3):
1020 - 1026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chick, P. Lehert, and F. Landron
Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence?
J Psychopharmacol,
December 1, 2003;
17(4):
397 - 402.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. F. Anton, D. H. Moak, L. R. Waid, P. K. Latham, R. J. Malcolm, and J. K. Dias
Naltrexone and Cognitive Behavioral Therapy for the Treatment of Outpatient Alcoholics: Results of a Placebo-Controlled Trial
Focus,
April 1, 2003;
1(2):
183 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Heinz, S. Lober, A. Georgi, J. Wrase, D. Hermann, E.-R. Rey, S. Wellek, and K. Mann
REWARD CRAVING AND WITHDRAWAL RELIEF CRAVING: ASSESSMENT OF DIFFERENT MOTIVATIONAL PATHWAYS TO ALCOHOL INTAKE
Alcohol Alcohol.,
January 1, 2003;
38(1):
35 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Krystal, J. A. Cramer, W. F. Krol, G. F. Kirk, R. A. Rosenheck, and the Veterans Affairs Naltrexone Cooperative Study
Naltrexone in the Treatment of Alcohol Dependence
N. Engl. J. Med.,
December 13, 2001;
345(24):
1734 - 1739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rubio, M. A. Jimenez-Arriero, G. Ponce, and T. Palomo
NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT
Alcohol Alcohol.,
September 1, 2001;
36(5):
419 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. R. Kranzler
PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH
Alcohol Alcohol.,
November 1, 2000;
35(6):
537 - 547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chick, R. Anton, K. Checinski, R. Croop, D. C. Drummond, R. Farmer, D. Labriola, J. Marshall, J. Moncrieff, M. Y. Morgan, et al.
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ABUSE
Alcohol Alcohol.,
November 1, 2000;
35(6):
587 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Palmer, K. Neeser, C. Weiss, A. Brandt, S. Comte, and M. Fox
THE LONG-TERM COST-EFFECTIVENESS OF IMPROVING ALCOHOL ABSTINENCE WITH ADJUVANT ACAMPROSATE
Alcohol Alcohol.,
September 1, 2000;
35(5):
478 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mann, D. Hermann, and A. Heinz
ONE HUNDRED YEARS OF ALCOHOLISM: THE TWENTIETH CENTURY
Alcohol Alcohol.,
January 1, 2000;
35(1):
10 - 15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Anton, D. H. Moak, L. R. Waid, P. K. Latham, R. J. Malcolm, and J. K. Dias
Naltrexone and Cognitive Behavioral Therapy for the Treatment of Outpatient Alcoholics: Results of a Placebo-Controlled Trial
Am J Psychiatry,
November 1, 1999;
156(11):
1758 - 1764.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. J. Mason, F. R. Salvato, L. D. Williams, E. C. Ritvo, and R. B. Cutler
A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence
Arch Gen Psychiatry,
August 1, 1999;
56(8):
719 - 724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren
Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine
Pharmacol. Rev.,
June 1, 1999;
51(2):
341 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Swift
Drug Therapy for Alcohol Dependence
N. Engl. J. Med.,
May 13, 1999;
340(19):
1482 - 1490.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Garbutt, S. L. West, T. S. Carey, K. N. Lohr, and F. T. Crews
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
JAMA,
April 14, 1999;
281(14):
1318 - 1325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Froehlich, N. E. Badia-Elder, R. W. Zink, D. E. McCullough, and P. S. Portoghese
Contribution of the Opioid System to Alcohol Aversion and Alcohol Drinking Behavior
J. Pharmacol. Exp. Ther.,
October 1, 1998;
287(1):
284 - 292.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. H. Krystal, I. L. Petrakis, E. Webb, N. L. Cooney, L. P. Karper, S. Namanworth, P. Stetson, L. A. Trevisan, and D. S. Charney
Dose-Related Ethanol-like Effects of the NMDA Antagonist, Ketamine, in Recently Detoxified Alcoholics
Arch Gen Psychiatry,
April 1, 1998;
55(4):
354 - 360.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1995
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
